Physician profile
Martin E Dennis
NPI 1184724098
$1,640.75
in general payments reported to CMS, 2019-2025
16 companies · $175 in 2025
The $175 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $307 · 2021: $378 · 2022: $365 · 2023: $7.41 · 2024: $63.88 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $246.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $654.14 | 2019-2024 | |
| Myovant Sciences INC. | $250.63 | 2021-2022 | |
| Therapeuticsmd, INC. | $173.64 | 2019-2020 | |
| Pfizer INC. | $87.01 | 2019-2021 | |
| Sage Therapeutics, LLC | $81.17 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $77.43 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $67.92 | 2019-2021 | |
| Astellas Pharma US INC | $51.38 | 2025 | Veozah |
| Mayne Pharma Commercial LLC | $40.20 | 2023-2025 | |
| Hologic Sales and Service, LLC | $32.63 | 2020-2021 | |
| Vertex Pharmaceuticals Incorporated | $31.65 | 2025 | |
| Organon LLC | $28.20 | 2021-2024 | |
| Allergan, INC. | $19.52 | 2019 | |
| Kedrion Biopharma INC. | $17.85 | 2019 | |
| Daiichi Sankyo INC. | $13.97 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $13.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Dennis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.